Literature DB >> 30447074

Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis.

M V Heppt1, T Steeb1, T Ruzicka1, C Berking1.   

Abstract

BACKGROUND: Actinic keratoses (AKs) are early in situ carcinomas of the skin caused by cumulative sun exposure. Cryosurgery is an easy and practicable lesion-directed approach for treatment of isolated lesions.
OBJECTIVES: To investigate whether an upfront combination of cryosurgery with a topical intervention is superior to cryosurgery alone for treatment of AK.
METHODS: We performed a systematic literature search in MEDLINE, Embase and CENTRAL and hand searched pertinent trial registers for eligible randomized controlled trials until 17 July 2018. Results from individual studies were pooled using a random effects model. The risk of bias was estimated with the Cochrane Risk of Bias Tool and the quality of evidence of the outcomes with the GRADE approach.
RESULTS: Out of 1758 records initially identified, nine studies with a total sample size of 1644 patients were included. Cryosurgery in combination with a topical approach showed significantly higher participant complete clearance rates than monotherapy [risk ratio (RR) 1·74, 95% confidence interval (CI) 1·25-2·43, I2 = 73%, eight studies]. The participant partial clearance rate was not statistically different (RR 1·64, 95% CI 0·88-3·03, I2 = 77%, three studies). The number of patients who completed the study protocol and did not withdraw due to adverse events was equal in both groups (RR 0·98, 95% CI 0·95-1·01, I2 = 75%, seven studies). The studies were estimated to have high risk for selective reporting bias.
CONCLUSIONS: Our results suggest the superiority of a combination regimen for AK clearance, with equal tolerability. This study highlights the importance of a field-directed approach in patients with multiple AKs or field cancerization.
© 2018 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30447074     DOI: 10.1111/bjd.17435

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Actinic Keratosis and Cutaneous Squamous Cell Carcinoma.

Authors:  Ralf Gutzmer; Susanne Wiegand; Oliver Kölbl; Kai Wermker; Markus Heppt; Carola Berking
Journal:  Dtsch Arztebl Int       Date:  2019-09-13       Impact factor: 5.594

Review 2.  A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions.

Authors:  Laura Del Regno; Silvia Catapano; Alessandro Di Stefani; Simone Cappilli; Ketty Peris
Journal:  Am J Clin Dermatol       Date:  2022-02-19       Impact factor: 6.233

Review 3.  Topical Pharmacotherapy for Actinic Keratoses in Older Adults.

Authors:  Piergiacomo Calzavara-Pinton; Irene Calzavara-Pinton; Chiara Rovati; Mariateresa Rossi
Journal:  Drugs Aging       Date:  2022-02-14       Impact factor: 3.923

4.  Spontaneous regression rates of actinic keratosis: a systematic review and pooled analysis of randomized controlled trials.

Authors:  Theresa Steeb; Anne Petzold; Annkathrin Hornung; Anja Wessely; Carola Berking; Markus V Heppt
Journal:  Sci Rep       Date:  2022-04-07       Impact factor: 4.379

Review 5.  Cryotherapy for Actinic Keratosis: Basic Principles and Literature Review.

Authors:  Mariachiara Arisi; Edoardo Guasco Pisani; Piergiacomo Calzavara-Pinton; Cristina Zane
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-03-05

6.  A Critical Appraisal of Evidence- and Consensus-Based Guidelines for Actinic Keratosis.

Authors:  Anja Wessely; Theresa Steeb; Franz Heppt; Annkathrin Hornung; Matthias D Kaufmann; Elias A T Koch; Frédéric Toussaint; Michael Erdmann; Carola Berking; Markus V Heppt
Journal:  Curr Oncol       Date:  2021-02-19       Impact factor: 3.677

7.  Acoustically Detonated Microbubbles Coupled with Low Frequency Insonation: Multiparameter Evaluation of Low Energy Mechanical Ablation.

Authors:  Mike Bismuth; Sharon Katz; Hagar Rosenblatt; Maayan Twito; Ramona Aronovich; Tali Ilovitsh
Journal:  Bioconjug Chem       Date:  2021-07-19       Impact factor: 6.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.